This article was originally published in The Gray Sheet
Financier Carl Icahn forgoes earlier plan to elect a rival slate of directors to the firm's board at the May 2002 annual meeting (1"The Gray Sheet" Nov. 26, 2001, p. 30). In a recent 13D filing with the Securities & Exchange Commission, Icahn maintained that depending upon market conditions, he may acquire or dispose of additional shares. Icahn previously proposed to acquire Visx for $32 per share in a hostile takeover bid last April...
You may also be interested in...
Financier Carl Icahn appears to have abandoned his $32 a share cash tender offer for Visx in favor of electing a rival slate of directors to the firm's board, a strategy that in the past has failed
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.